Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Features

Features
Optimizing gene transfection strategies for the targeted treatment of rheumatoid arthritis

18 Aug 05

Rheumatoid arthritis affects an estimated 2.1 million Americans. The initial success of biologics that neutralize TNF alpha mean that these therapeutics dominate the US and European rheumatoid arthritis markets. Although the development of biologics has revolutionized treatment of rheumatoid arthritis therapies remain far from optimal. Since biologics are peptidic in nature they must be administered by injection. Moreover, multiple dosing is required and this can be disruptive to the patient.
LeadDiscovery

FGF-21 as a candidate for the treatment of diabetes

18 Aug 05

It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. Despite the presence of well established treatments of diabetes significant unmet needs remain driving a large body of research and development activity. The highlighted JCI paper described work by Lilly researchers advancing FGF-21 or its mimics as a novel therapeutic candidates for the treatment of diabetes.
LeadDiscovery

Actin Inhibition: The identification of PTX-2 as a novel anti-mitotic agent that selectively induces apoptosis in p53 deficient cancer cells

18 Aug 05

Although cytotoxics agents represent a cornerstone of oncology, toxicity and drug resistance has driven the development of targeted anticancer therapies. The current study highlights a novel antimitotic agent, PTX-2. This molecule, like the Taxol and Taxotere, blocks the cell cycle in late mitosis channelling cells into an apoptotic program. In direct contrast to Taxol and Taxotere, PTX-2 targets cells with p53 mutations; the plant alkaloids on the other hand are relatively insensitive in such c
LeadDiscovery

Targeting beta-catenin by celecoxib (Celebrex) as an anti-cancer mechanism of action and as a lead for the identification of improved oncology agents

18 Aug 05

Despite the cardiovascular risks that have recently emerged following prolonged treatment with COX-2 inhibitors, this class of drug continues to receive interest as an approach to chemoprevention. Celebrex, which was approved in 1998 for the treatment of familial adenomatous polyposis (FAP) has been shown to reduce the development of precancerous colorectal polyps by 28%. Data recently highlighted in the FASEB journal suggests that at least part of the efficacy of celebrex may be related to the
LeadDiscovery

The Facts About Job Satisfaction

15 Aug 05

Job satisfaction is an attitude that employees have about their work and is based on numerous factors, both intrinsic and extrinsic to the individual.
i3 Pharma Resourcing

Selection and Assessment Day

15 Aug 05

Clinical Research Academy has decided to implement a sure-fire way of finding top candidates for Clinical Research Associate (CRA) posts – by running a Selection and Assessment Day. The first was held at the end of July in Marlow in the UK.
Kieran.Engels

New beginnings for brain cancer treatment

06 Aug 05

While brain cancer may be one of the rarer cancers, the outlook for those diagnosed is bleak. For patients with glioblastoma multiforme (GBM) - the most aggressive form of brain cancer - average survival is approximately one year. However the recent supplementary approval of temozolomide for use in first-line treatment may represent the first step in a more 'personalized' approach to GBM.
Datamonitor

Xolair's proposed EU label may prove disappointing for Novartis

05 Aug 05

Novartis has received a positive opinion from a European committee recommending marketing authorization be granted to Xolair for severe persistent allergic asthma. Although Xolair has delivered impressive results, the restrictive label, together with high treatment costs, will limit its sales potential in the EU, meaning Novartis, and partner Genentech, may prefer to focus on the US market.
Datamonitor

Chocolate – not quite medicinal just yet….

05 Aug 05

Few who love its taste associate it with good health, but recent reports that a confectionary company was seriously examining the pharmaceutical potential of chocolate achieved widespread international media coverage.
Dr Faiz Kermani

Milestone in the development of Histone Deacetylase Inhibitors

05 Aug 05

This alert is brought to you by LeadDiscovery and concerns today's announcement by Celera Genomics that clinical evaluation of their HDAC inhibitor CRA-024781 is about to commence. The press release is featured on today's edition of DailyUpdates-Oncology.
LeadDiscovery

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.